VitalDose® EVA excipients - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Participate in the VitalDose excipient discussion. Ken Anderson of Celanese shares insights into EVA excipients technology and invites you to ask questions about one of the most versatile polymers utilized in the pharmaceutical industry.

Are you in search of routes of administration that can breathe new life into your expiring drug patents? Want to learn more about excipients technology for use in novel controlled released products? Find answers to these questions and more at the recently launched blog – – where Celanese EVA Performance Polymers technical leader, Ken Anderson, Ph.D. will provide regular updates and summaries on the latest research pertaining to EVA excipients.

In participating in the new VitalDose blog, you will learn:

  • The latest news in VitalDose ethylene vinyl acetate (EVA) excipients
  • Technical data on this technology and its applications
  • Solutions to formulation challenges.

EVA polymers have been used for many years in a variety of pharmaceutical and medical device products.

Tailor the dosing and delivery of your API

  • Formulation design versatility
  • Customizable delivery and release profiles
  • Manufacturing process versatility
  • Multiple routes of administration

Learn more about EVA polymers at the website or e-mail us at

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
FindPharma Custom Search

Click here